With the S&P 500 reaching new highs last week, investors appear to be taking an optimistic view of the overall stock market. However, not all stocks are participating in this rally. Some high-quality companies are still trading at beaten-down valuations, making them attractive value plays for investors. As monetary policy continues shifting in a more dovish direction, we could be at an inflection point where these value stocks start to regain their previous luster.That’s why I think now is an opportune time ...

After eight-straight monthly losses starting in April 2023, the shares of pharmaceutical concern Bristol-Meyers Squibb Co (NYSE:BMY) started to rebound in December, though were swiftly rejected by the 80-day moving average at the start of the year. Now, it looks like that bounce was indeed short-lived, as BMY is seeing even more pressure on the charts after its recent dip. According to Schaeffer's Senior Quantitative Analyst Rocky White, Bristol-Meyers stock is within one standard deviation of its 50-day an ...

The FDA has asked Gilead Sciences, Inc. (GILD) , Johnson & Johnson (JNJ) and Novartis (NVS) to add “boxed warning” to the labels of their chimeric antigen receptor (CAR) T-cell immunotherapies, per Reuters.The regulatory body sent letters to these companies stating that it had identified adverse events and clinical trial reports describing T-cell malignancies.We remind readers that in November 2023, the FDA announced that it was investigating the identified risk of T-cell malignancy in patients who received ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb. “The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in ...

Parradee Kietsirikul Introduction Last year, we saw an uptick in M&A from big pharma to combat the significant drug patent cliff later in the decade. Amongst the worst anticipated patents cliffs is Bristol Myers Squibb (NYSE:BMY) who announced a number of deals into the end of 2023. Last year former COO and now current CEO Chris Boerner revised the $10bn-13bn sales target for new drugs by 2025 to $10bn by 2026, raising concerns over the company ability to completely offset patent loss in later years. Op ...

Bristol Myers Squibb (BMY) closed at $49.57 in the latest trading session, marking a -1.08% move from the prior day. This change lagged the S&P 500's 0.22% gain on the day. Meanwhile, the Dow experienced a rise of 0.36%, and the technology-dominated Nasdaq saw an increase of 0.32%.Shares of the biopharmaceutical company have depreciated by 4.17% over the course of the past month, underperforming the Medical sector's gain of 2.3% and the S&P 500's gain of 1.61%.The upcoming earnings release of Bristol Myers ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28% in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) vs. sunitinib after eight years, regardless of International Metastatic RCC Database Consortium (IMDC) risk group. Patients treated with Opdivo plus Yervoy maintained su ...

Clinical Trial Results - The CheckMate -9ER trial demonstrated superior progression-free survival (PFS) and objective response rates (ORR) for Opdivo plus CABOMETYX compared to sunitinib in patients with advanced or metastatic renal cell carcinoma (RCC) [1][2] - Median PFS was 16.4 months for Opdivo plus CABOMETYX vs 8.4 months for sunitinib, with a hazard ratio (HR) of 0.58 [2] - Median overall survival (OS) was 46.5 months for Opdivo plus CABOMETYX vs 36.0 months for sunitinib, with an HR of 0.77 [2] - ORR was 55.7% for Opdivo plus CABOMETYX vs 27.7% for sunitinib, with complete response (CR) rates of 13.6% vs 4.6% respectively [2] - The combination showed durable benefits across patient subgroups, including intermediate-/poor-risk and favorable-risk groups [3][4] Safety and Efficacy - No new safety concerns were identified in the follow-up analysis, with any-grade treatment-related adverse events (TRAEs) occurring in 97.5% of Opdivo plus CABOMETYX patients vs 93.1% for sunitinib [2] - Grade ≥3 TRAEs occurred in 67.5% of Opdivo plus CABOMETYX patients vs 55.3% for sunitinib [2] - The combination demonstrated durable and clinically meaningful benefits in health-related quality of life compared to sunitinib [1] Industry and Company Impact - The results reinforce the role of Opdivo plus CABOMETYX as a first-line treatment option for advanced RCC, with potential to improve long-term survival outcomes [5][6] - Bristol Myers Squibb and Exelixis continue to collaborate on advancing treatment regimens for advanced cancers, including genitourinary cancers [5][66] - The trial results highlight the ongoing need for effective therapeutic options for patients with advanced or metastatic RCC, particularly those with challenging-to-treat disease burdens [5][6]

BALA CYNWYD, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Karuna Therapeutics, Inc. (Nasdaq – KRTX) Under the terms of the Merger Agreement, Karuna Therapeutics will be acquired by Bristol Myers Squibb (NYSE:BMY) in an all-cash tran ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of chemotherapy (mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab) as a first-line treatment for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). The dual immunotherapy combination of Opdivo and Yervoy d ...